ENDEAVOR (Completed)
to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants with Heart Failure With Left Ventricular Ejection Fraction > 40%
- Medicine
- AZD4831
- Population
- Heart failure
- Phase
- III
- Starting year
- 2022